share_log

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $71

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $71

摩根士丹利維持對Axsome Therapeutics的同等權重,將目標股價下調至71美元
Benzinga Real-time News ·  2022/09/30 08:32

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and lowers the price target from $75 to $71.

摩根士丹利分析師維克拉姆·普羅希特維持Axsome Therapeutics(納斯達克股票代碼:AXSM)的權重相等,並將目標股價從75美元下調至71美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論